Introduction {#Sec1}
============

Fraser syndrome (FS) is an autosomal recessive disease characterised by cryptophthalmos (hidden eyes), cutaneous syndactyly (fused digits), ambiguous genitalia and renal and upper respiratory (larynx and trachea) tract malformations \[[@CR1]--[@CR3]\]. Up to about 30% of cases have bilateral renal agenesis, while others have one or more of the following: unilateral renal agenesis and uni- or bilateral cystic, dysplastic or hypoplastic kidneys \[[@CR2], [@CR3]\]. FS is rare, occurring in around 11/100,000 stillbirths and 0.4/100,000 live births, and a significant subset of the latter die in the first year with renal and/or respiratory failure \[[@CR2], [@CR3]\]. Survival to old-age is, however, possible when functional kidney tissue is present \[[@CR4]\].

Some individuals with FS have homozygous mutations of either *FRAS1* (*Fraser syndrome 1*) \[[@CR5]\] or *FREM2* (*FRAS1-related extracellular matrix protein 2*) \[[@CR6]\]. Mice with homozygous null mutations of either gene have developmental anomalies phenocopying human FS \[[@CR5]--[@CR8]\]. The penetrance of renal agenesis is strain dependant, approaching 100% in the C57BL-6 J background \[[@CR8]\]. Outbred mice with *Fras1* or *Frem2* mutations have a lower incidence of renal agenesis and, in this context, mice with compound *Fras1/Frem2* mutations have kidneys with multiple cysts arising from the distal nephron and collecting ducts, as respectively assessed by uromodulin expression and binding of *Dolichos biflorus* lectin \[[@CR6]\].

Fras1 and Frem2 proteins localise in embryonic basement membranes where they are thought to mediate physical (e.g. in skin) or signalling (e.g. in metanephric kidney induction) interactions between epithelia and adjacent mesenchymal cells \[[@CR9], [@CR10]\]. Delivery of Fras1 to the plasma membrane is mediated by interaction with glutamate receptor-interacting protein 1 (Grip1) \[[@CR11], [@CR12]\]. Extracellularly, Fras1 and Frem2 associate with each other and also with a related molecule called Frem1 \[[@CR9], [@CR10], [@CR13], [@CR14]\]. Mice with homozygous mutations of *Frem1* \[[@CR15]\] or *Grip1* \[[@CR11]\] phenocopy human FS, and humans with *FREM1* mutations have an FS-like syndrome with prominent hindgut and renal tract anomalies \[[@CR16]\]. Frem3 is another member of the Fras protein family \[[@CR10], [@CR17]\], but human *FREM3* mutations have yet to be reported.

Little is known about whether and where molecules encoded by FS genes might be expressed in postnatal kidneys. In this study, we investigated *Frem2* expression in healthy and *congenital polycystic kidney* (*cpk*) mouse kidneys using a *LacZ* reporter gene and quantified *Fras* family transcripts. Fras1 immunohistochemistry was undertaken in cystic kidneys from *cpk* mice and *PCK* (*Pkhd1*) mutant rats \[models of autosomal recessive polycystic kidney disease (PCD)\] and in wild-type metanephroi rendered cystic by dexamethasone exposure.

Materials and methods {#Sec2}
=====================

Experiments were undertaken in accordance with the UK Home Office Animal (Scientific Procedures) Act 1986. In the *my*^*KST*^ mouse, *Frem2* is mutated by a gene trap, and *LacZ* reporter gene expression mimics tissue patterns of endogenous *Frem2* transcripts \[[@CR6]\]. Homozygous *my*^*KST*^ mutants have the myencephalic blebs phenotype featuring external eye anomalies, syndactyly and renal malformations, similar to human FS. For simplicity, we hereafter refer to this allele as *Frem2*^*LacZ*^ and, as a prelude to studies described below, it was propagated in a C57BL-6 J background for over six generations by crossing heterozygous (*Frem2*^*LacZ/+*^) with wild-type mice. For some experiments, we bred the *Frem2*^*LacZ*^ allele into mice carrying the *cpk* allele, also maintained on a C57BL-6 J background. *cpk* mice have a mutation of *cystin* which encodes a protein localised to the primary cilium \[[@CR18]\]. Although a mutation of a homologous human gene has yet to be reported, murine *cpk/cpk* kidneys anatomically resemble those found in human autosomal recessive polycystic kidney disease (PKD) (ARPKD) \[[@CR19]\].

We used the X-gal technique to generate an easily detected blue-coloured precipitate wherever the *LacZ* reporter gene was expressed from the *Frem2* locus \[[@CR6]\]. This was undertaken in whole mounts, and histology sections were prepared from these, as described \[[@CR20]\]. Using this protocol, no unspecific staining was observed in foetal or adult kidneys lacking the *Frem*^*LacZ*^ allele as has been demonstrated by Yuan et al. \[[@CR20]\] and also in the [Results](#Sec3){ref-type="sec"} described below (see Fig. [2](#Fig2){ref-type="fig"}g, h; Fig. [3](#Fig3){ref-type="fig"}e--h). Paraffin-embedded kidneys were sectioned (thickness 5 μm) and, after dewaxing, were variously counterstained with (1) haematoxylin to detect cell nuclei, (2) antibody to uromodulin to detect thick ascending limbs of loops of Henle and (3) antibody to aquaporin-2 to detect collecting ducts \[[@CR20]--[@CR22]\]. Other sections were reacted with anti-Fras1 antibody (HPA011281; Sigma, St. Louis, MO) raised in rabbits against a 102 amino acid human epitope that is 87% conserved in murine Fras1. Primary antibodies were detected using appropriate secondary antibodies and a peroxidase-based system, generating a brown colour \[[@CR20]--[@CR22]\]. Representative staining patterns for at least three organs for each time point were obtained. In cystic kidneys, we quantified the proportions of cross-sectional areas of kidneys which were occupied by cysts, as described \[[@CR22]\].

Glomerular numbers per kidney were counted after gentle acid dissociation of 2-week-old kidneys, as previously described \[[@CR23]\]. RNA was extracted from wild-type and *cpk/cpk* kidneys, and levels of *Fras*-related (i.e. *Fras1*, *Frem1*, *Frem2*, *Frem3* and *Grip1*) were measured using the RT^2^ Profiler PCR Array system, as previously described \[[@CR22]\]. Levels were factored for a panel of transcripts encoded by housekeeping genes, as described \[[@CR22]\]. Student's *t*-test was used to compare data sets.

After determining that Fras1 was prominently expressed in *cpk* cysts (see [Results](#Sec3){ref-type="sec"}), Fras1 immunohistochemistry was undertaken in two other cystic models. The first of these was embryonic day 13 (E13) wild-type CD1 mouse metanephroi explanted in organ culture and grown in serum-free, defined media containing 0.47 μM dexamethasone, as previously described \[[@CR22]\]. In this model, which may represent a paradigm for the modulation of cystogenesis by glucocorticoid "foetal programming" \[[@CR24]\], nephrons become cystic after 6 days in culture \[[@CR22]\]. The second model was 8-week-old wild-type and PCK homozygous mutant kidneys (Charles River) which contain predominantly distal nephron and collecting duct cysts \[[@CR25]\]. These rats carry a mutation in *Pkhd1*, the homologous gene being mutated in human ARPKD \[[@CR26]\].

Results {#Sec3}
=======

*Frem2*^*LacZ/+*^ kidneys are structurally normal {#Sec4}
-------------------------------------------------

In preliminary experiments, we noted that E16 homozygous *Frem2*^*LacZ/LacZ*^ mutant mice lacked kidneys (data not shown). Conversely, no gross anomalies of shape or size of either kidneys or lower renal tracts were observed in several tens of autopsies of foetal and postnatal heterozygous (*Frem2*^*LacZ/+*^ ) mice. With regard to kidney weights in 14-day-old postnatal mice, after nephrogenesis has finished \[[@CR27]\], there was no significant difference (*P* = 0.61) between wild-type and heterozygous organs \[mean ± standard deviation (SD); *Frem2*^*+/+*^, 42 ± 7 mg (*n* = 8); *Frem2*^*LacZ/+*^ , 40 ± 5 mg (*n* = 9)\]. Similarly, there was no significant difference (*P* = 0.45) between estimated numbers of glomeruli per kidney between the two genotypes at this stage \[*Frem2*^*+/+*^, 10.6 ± 1.2 × 10^3^ (*n* =13; *Frem2*^*LacZ/+*^, 11.1 ± 1.5 × 10^3^ (*n* = 17)\]. *Frem2*^*LacZ/+*^ kidneys could not be distinguished from wild-type littermate organs based on histology (data not shown). These results suggest that *Frem2* haploinsuffiency does not overtly affect nephrogenesis.

*Frem2* is expressed in epithelia in the nephogenic cortex {#Sec5}
----------------------------------------------------------

In mice, layers of nephrons are generated in the superficial (nephrogenic) cortex beginning in the foetal period and continuing until the middle of the first postnatal week \[[@CR27], [@CR28]\]. During this process, termini of ureteric bud (UB) branches are flanked by primitive nephrons which have been induced to differentiate into epithelia from renal mesenchymal cells. In histology sections of E16, E18 and postnatal day 3 (P3) *Frem2*^*LacZ/+*^ kidneys, transgene expression was detected in the nephrogenic cortex in UB stalks and tips (Fig. [1](#Fig1){ref-type="fig"}a). Differentiating nephrons adjacent to UBs also expressed *LacZ*, most prominently in the distal limb of the S-shaped body where the proximal tubule forms (Fig. [1](#Fig1){ref-type="fig"}a). Subsets of podocytes in maturing, capillary-loop stage glomeruli also expressed the transgene (Fig. [1](#Fig1){ref-type="fig"}a, b). At these stages, cortical (Fig. [1](#Fig1){ref-type="fig"}b) and medullary (Fig. [1](#Fig1){ref-type="fig"}c) collecting ducts also expressed *LacZ*. These histological expression patterns had counterparts that became evident upon inspection of the whole mount preparations. At E16, expression was prominent in arborising UB branches and collecting ducts (Fig. [2](#Fig2){ref-type="fig"}a, b), and urothelium in the ureter also expressed *Frem2* at this stage (Fig. [2a](#Fig2){ref-type="fig"}). Clusters of blue "leopard spots" (each cluster representing a UB terminus surrounded by primitive nephrons) were detected on outer surfaces of E18 *Frem2*^*LacZ/+*^ and P3 kidneys (Fig. [2](#Fig2){ref-type="fig"}c, e), while sagittal sections at these stages revealed prominent staining in the nephrogenic zone (Fig. [2](#Fig2){ref-type="fig"}d, f). As expected, at P3 (Fig. [2](#Fig2){ref-type="fig"}g, h) and at other stages (data not shown), no specific signal was detected after X-gal staining of wild-type kidneys.Fig. 1*LacZ* expression in histology sections of *Frem2*^*LacZ/+*^ kidneys. All sections were from kidneys stained using the X-gal procedure, with a *light-blue*colour indicating sites of transgene expression. All sections were counterstained with haematoxylin (*dark-blue* nuclei). **a--c** Sections from the same embryonic day (*E16*) metanephric kidney, moving from superficial to deeper areas in the organ. In the nephrogenic (**a**) and deeper cortex (**b**), *Frem2/LacZ* was expressed in ureteric bud branches (*u*), S-shaped bodies (*s*) and subsets of podocytes (*arrows*) of immature glomeruli. The transgene was expressed by large medullary collecting ducts (**c**). **d**--**e** Adult kidneys. In the outer medulla (**d**), tubules expressing *LacZ* lie alongside thick ascending limbs of loops of Henle which express uromodulin (*brown*). Tubules which express *Frem2/LacZ* also expressed aquaporin-2 (*brown*), defining them as collecting ducts (**e**). **f** In adult kidneys, podocytes do not express *Frem2/LacZ*. Transgene expression is noted in smooth muscle cells in a nearby arteriole (*arrows*). **a--e** magnification ×40, **f** magnification ×63Fig. 2Whole-mount X-gal staining. All images are of *Frem2*^*LacZ/+*^ kidneys, except for **g** and **h** which are wild-type organs. **a**, **c**, **e**, **g**, **i** Views of outside surfaces of kidneys; all other images are of sagittal sections. At E16, the arborising ureteric bud branches and their tips in the nephrogenic zone express the reporter gene (*blue colour*). Note that the urothelium of the ureter also expresses *Frem2/LacZ* at this stage (*arrow*). At E18, the external pattern becomes more complex, with clusters of *blue*, each representing a ureteric bud tip flanked by the forming nephrons. A similar pattern is noted at postnatal day 3 (*P3*), representing a later wave of nephrogenesis. In the adult kidney, transgene expression is most prominent in the outer medulla and papilla, representing collecting ducts (compare with Fig. [1](#Fig1){ref-type="fig"}e). Radial *blue streaks* in the outer cortex represent expression in small arteries (compare with Fig. [1](#Fig1){ref-type="fig"}f). **g**, **h** Wild-type kidneys; X-gal staining did not result in a significant *blue* signal

*Frem2* is expressed in diverse structures in the normal adult kidney {#Sec6}
---------------------------------------------------------------------

Inspection of whole mounts at 21 days and 6 weeks (Fig. [2](#Fig2){ref-type="fig"}i, j and data not shown) revealed minimal transgene expression in the outer cortex of the kidney. In contrast, a band of prominent expression was detected in the outer medulla, and there was also marked expression in the deep medulla/papilla. *Frem2*^*LacZ*^ was expressed in medullary tubules which immunostained for aquaporin-2 but not uromodulin, defining these structures as collecting ducts and excluding the possibility that thick ascending limbs of loops of Henle expressed *Frem2/LacZ* (Fig. [1](#Fig1){ref-type="fig"}d, e). Walls of renal arteries expressed the transgene (Figure [1](#Fig1){ref-type="fig"}f), but transgene expression was not detected within mature glomerular tufts (Fig. [1](#Fig1){ref-type="fig"}f).

*Fras1* transcripts are upregulated and *Frem3* downregulated in *cpk* kidneys {#Sec7}
------------------------------------------------------------------------------

Maintained on a C57BL-6 J background, *cpk/cpk* mice undergo two phases of kidney cystogenesis \[[@CR21], [@CR29]\]: (1) during the first postnatal week, proximal tubules form small cysts; (2) thereafter, cysts derived from collecting ducts cause massive nephromegaly, with death from renal excretory failure occurring from the fourth postnatal week onwards. Thus, for our analyses, we studied day 14 postnatal *cpk/cpk* mice, at which time the histology is dominated by collecting duct cysts but the animals are not yet overtly unwell from uraemia. As assessed by qPCR, there was a significant (*P* = 0.025) 3.5-fold upregulation of *Fras1*, based on our comparison of four *cpk/cpk Frem2*^*+/+*^ kidneys with four kidneys from mice which were wild type at the both the *cpk* and *Frem2* loci. However, there were no significant differences between polycystic and non-cystic kidneys in the expression levels of *Frem1* (*P* = 0.9), *Frem2* (*P* = 0.5) or *Grip1* (*P* = 0.3). Levels of *Frem3* transcripts were markedly and significantly (12.4-fold; *P* = 0.001) downregulated in *cpk/cpk* versus non-cystic kidneys.

Expression of FS molecules in polycystic kidney epithelia {#Sec8}
---------------------------------------------------------

We crossed the *Frem2*^*LacZ*^ allele into *cpk* mice and examined the kidneys of *cpk/cpk* mice which also carried one *LacZ* allele. The transgene was expressed in epithelia of small cortical cysts (Fig. [3](#Fig3){ref-type="fig"}a, b) and---but only faintly---in massive cysts deeper in the organ (Fig. [3](#Fig3){ref-type="fig"}c). Undilated tubules between cysts strongly expressed *Frem2/LacZ* (Fig. [3](#Fig3){ref-type="fig"}c, d). In histology sections of *cpk/cpk* kidneys, there was no significant difference between the area occupied by cysts in *Frem2*^*+/+*^ organs (65 ± 11%; *n* = 9) compared with *Frem2*^*LacZ/+*^ (62 ± 6%; *n* = 8) organs. In sections of wild-type mouse kidneys aged 14 days, Fras1 was immunodetected in cortical and medullary tubules with collecting duct profiles (Fig. [3](#Fig3){ref-type="fig"}e, f). In postnatal day-14 *cpk/cpk Frem2*^*+/+*^ kidneys, intense Fras1 immunoreactivity was noted in cyst epithelia (Fig. [3g](#Fig3){ref-type="fig"}). In sections of *cpk/cpk Frem2*^*LacZ/+*^ kidneys treated with X-gal and then immunostained for Fras1, it was apparent that undilated tubules between cysts expressed *Frem2* but not Fras1 (Fig. [3](#Fig3){ref-type="fig"}d). Sections of *cpk/cpk Frem2*^*+/+*^ polycystic kidneys which had undergone identical immunohistochemical procedures but with the primary antibody omitted showed, as expected, no signals (Fig. [3](#Fig3){ref-type="fig"}h). Fras1 was also immunodetected in cystic kidney epithelia within dexamethasone-exposed explanted wild-type metanephroi and in larger cysts, most likely collecting-duct derived structures \[[@CR25]\], in the deep cortex and outer medulla of adult PCK kidneys (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Fraser syndrome gene expression in *congenital polycystic kidney*s (*cpk*). All frames depict histology sections cut from whole mounts which had been reacted with X-gal to detect *LacZ* reporter gene expression. All images show postnatal day-14 *cpk/cpk* kidneys apart from **e** and **f** which are images of kidneys from non-*cpk* littermates. Organs depicted in **a**--**d** are from mice which also carry one *Frem2*^*LacZ*^ allele, whereas organs depicted in **e**--**h** are from mice which are wild type at the *Frem2* locus. **d**--**h** Sections were immunostained for Fras1, but the primary antibody was omitted in **h**. **a**, **b**. *Frem2/LacZ* expression (*light blue*) in small cortical cysts. **c** Less marked transgene expression in attenuated epithelia lining massive cysts deep in the *cpk* kidney. **c**, **d**, note that undilated tubules between large cysts express *Frem2/LacZ*. **e**, **f** Fras1 was immunodetected (*brown*) in subsets of cortical and medullary tubules in non-cystic kidneys. **d**, **g** Fras1 was intensely expressed in cystic epithelia within *cpk* kidneys. In **d**, note that undilated tubules between cysts express *Frem2/LacZ* but not Fras1, a result supporting the notion that the Fras1 antibody is non-reactive to Frem2 and specific for Fras1. In **e**--**h**, no (*light blue*) X-gal reactivity was detected in these kidneys from mice which did not carry the *Frem2*^*LacZ*^ allele. No immunohistochemical (*brown*) signal was found when the primary antibody to Fras1 was omitted (**h**). Magnification of all images ×40Fig. 4Fras1 immunohistochemistry in dexamethasone-induced and *Pkhd1* mutant mice (PCK) cysts, a model of polycystic kidney disease. All sections were counterstained with haematoxylin (*blue* nuclei). Organs depicted in **a**--**d** are wild-type mouse metanephric organ cultures, with **a** and **b** grown in vehicle-only and **c** and **d** exposed to dexamethasone. **a** and **c** Primary antibody was omitted, and no significant immunohistochemical (*brown*) signal was detected in normal structures or cysts (*asterisks*). In explants grown in vehicle only (**b**), weak Fras1 signal was noted in branching collecting ducts (*cd*). **d** Fras1 was immunodetected in epithelia of dexamethasone-induced cysts (*asterisks*). **e** Adult wild-type rat kidney; no significant Fras1 signal was detected. **f** PCK kidneys; smaller cysts (*+*) displayed minimal Fras1 immunostaining, while a prominent signal appeared in epithelia lining large cysts (*arrows*). Magnification of all images ×40

Discussion {#Sec9}
==========

*Fras1* and *Frem2* transcripts are known to be expressed in the E11 mouse UB \[[@CR6], [@CR8]\], and previous studies have immunodetected Fras1 in UB epithelia \[[@CR7], [@CR8]\]. In *Fras1* null mutant embryos generated on a C57BL-6 J background, the UB fails to penetrate renal mesenchyme, and this is followed by apoptotic involution of the rudiment \[[@CR5], [@CR8]\]. *Fras1* transcripts are also expressed in vesicles and S-shaped bodies, early nephron structures and podocytes of foetal glomeruli \[[@CR8]\]. Notably, in outbred adult mice with compound *Fras1/Frem2* mutations, kidneys contain multiple cysts lined by apoptotic and proliferative epithelia \[[@CR6]\], and the same organs contain glomeruli with perturbed nephrin, podocin, integrin α3 and fibronectin expression \[[@CR8]\].

Together, these previous observations lead to the hypothesis that *Fras1* and *Frem2* genes maintain the integrity of diverse renal epithelia as well as being involved in the initiation of the metanephric kidney. Until the study reported here, however, little data have been available on the expression of FS family molecules from late gestation through to postnatal maturation. We found that *Frem2* has a complex and dynamic expression pattern in maturing nephrons, including transient podocyte expression, and that it is expressed in both maturing and adult collecting ducts. Furthermore, Fras1 protein was detected in postnatal collecting ducts. A difference between expression of the two genes was that only Frem2 was found in the smooth muscle of arterial walls; apart from this, at least within normal kidneys, the expression of both these FS molecules is epithelial-specific.

In our study, we measured glomerular numbers in postnatal kidneys and found that *Frem2* heterozygous mice did not have a significantly different result compared with wild-type littermates. We used an acid dissociation technique \[[@CR23]\] rather than a non-biased sterology method for counting glomeruli \[[@CR30]\]. Although the latter is considered the "gold standard", given that tissue architecture was similar in the heterozygous and wild-type mouse kidneys, the counts using the acid dissociation method can be interpreted to mean that *Frem2* halploinsuficiency is unlikely to confer an important difference in numbers. Very recently, a heterozygous missense *FREM2* mutation has been reported in a patient with unilateral renal agenesis \[[@CR31]\]. In the context of our study of heterozygous *Frem2* mutant mice in the C57BL-6 J background, we have yet to observe either unilateral or bilateral absent kidneys on autopsy. It remains possible that haploinsufficiency of *Frem2* might cause renal malformations in mice of different background strains, or that the missense *FREM2* change reported in a patient with agenesis \[[@CR31]\] could be operating in a dominant-negative manner. An alternative explanation for the human finding is that the *FREM2* missense change simply represents a rare, non-pathogenic variant found by co-incidence in an individual with agenesis.

As discussed in the [Introduction](#Sec1){ref-type="sec"}, *Fras1* and *Frem2* code for basement membrane-associated proteins \[[@CR9], [@CR10]\]. Notably, there exists a human genetic disease called HANAC (hereditary angiopathy with nephropathy, aneurysms and muscle cramps) syndrome in which the dominant mutation of another basement membrane gene, *COL4A1*, coding for procollagen type IV α1, is associated with the postnatal growth of kidney cysts \[[@CR32]\]. In this disease, tubule dilatation is perhaps triggered by weakened physical support conferred by a defective basement membrane, and it is possible that this change serves as a paradigm for cystogenesis associated with *Fras1/Frem2* mutations. Previous studies have shown that the manipulation of specific genes expressed in *cpk* kidney epithelia can modify the size of kidney cysts. As examples, haploinsufficiency of the *Paired box-2* transcription factor reduces cystogenesis, probably by enhancing apoptosis in cystic epithelia \[[@CR33]\], whereas genetic downregulation of galectin-3, a secreted molecule located in the cilia and basal surfaces of collecting ducts, increases cyst growth by unknown mechanisms \[[@CR21]\].

Based on the fact that *Fras1/Frem2* mice can have cystic kidneys \[[@CR6]\], and our current observations that (especially non-massive and thus presumably growing) cysts in *cpk/cpk* kidneys clearly express *Frem2*, we predicted that a reduction in expression level of *Frem2* might lead to a more severe cystic phenotype. This was not, however, found to be the case, at least as assessed by the measurement of kidney cross-sectional areas occupied by cysts in 14-day-old mice. Perhaps a more profound experimental reduction of *Frem2* expression would affect *cpk* cystogenesis but because homozygous null mutant *Frem2* mice do not develop kidneys, this idea can not be tested with the experimental tools currently available to us.

*Fras1* transcripts were significantly upregulated in *cpk/cpk* kidneys compared with those of non-cystic littermates. A trivial explanation for increased *Fras1* mRNA levels would be that, at 14 days of age, a greater proportion of the polycystic kidney is occupied by collecting duct epithelia compared with a non-cystic organ and that collecting ducts normally express this gene. On the other hand, we also found that Fras1 was immunolocalised in *cpk* cysts, with intense signals. Having made this observation, we undertook Fras1 immunostaining in two other renal cystic models and detected the protein in dexamethasone-induced cysts in explanted wild-type organs and in larger cysts in the PCK rat model of human ARPKD. These observations, namely, that Fras1 is expressed in diverse models of kidney cysts, can be interpreted in two ways. Firstly, Fras1 expression may be an unspecific reaction in cystic epithelia. Alternatively, Fras1 may be playing active roles in the biology of cyst growth. In the current study, we did not have access to a reliable antibody to Frem2, and thus could not determine Frem2 tissue localisation in the two extra models.

Finally, of note, *cpk/cpk* kidneys showed marked down-regulation of the *Fras* family gene, *Frem3*. Although the function of this gene in mammals is yet to be defined, it has been reported that the protein is widely expressed in basement membranes \[[@CR10], [@CR17]\] and that *frem3* is required for skin integrity in embryonic fish \[[@CR34]\].

Collectively, the results of our study are consistent with the hypothesis that FS family molecules may play roles in diverse kidney epithelia. In future studies, this contention would be best tested by conditional deletion of specific genes in specific nephron segments \[[@CR35]\] and collecting ducts \[[@CR36]\] in healthy and cystic kidneys.
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